ABSTRACT
-The continuous infusion of recombinant activated factor VII (rFVIIa) was first described
in 1996. Because of the significant benefits in convenience and cost that can be achieved
with this mode of administration compared with bolus doses, the method was quickly
adopted, albeit with many local variations. Some of those have been less favorable,
resulting in hemorrhagic complications. The potential pitfalls and experiences from
a large number of cases collected in an international registry of continuous infusion
with rFVIIa are reviewed. The only indications discussed here are hemophilia A or
B with inhibitors or acquired hemophilia. Different recommendations may apply for
other indications.
KEYWORD
Hemophilia A - inhibitors - recombinant factor VIIa - continuous infusion - hemorrhage
